JP2022506299A5 - - Google Patents
Info
- Publication number
- JP2022506299A5 JP2022506299A5 JP2021523599A JP2021523599A JP2022506299A5 JP 2022506299 A5 JP2022506299 A5 JP 2022506299A5 JP 2021523599 A JP2021523599 A JP 2021523599A JP 2021523599 A JP2021523599 A JP 2021523599A JP 2022506299 A5 JP2022506299 A5 JP 2022506299A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- salt
- pharmaceutically acceptable
- cancer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18204423.0 | 2018-11-05 | ||
| EP18204423 | 2018-11-05 | ||
| PCT/EP2019/079601 WO2020094471A1 (en) | 2018-11-05 | 2019-10-30 | Cytostatic conjugates with integrin ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506299A JP2022506299A (ja) | 2022-01-17 |
| JP2022506299A5 true JP2022506299A5 (enExample) | 2022-08-17 |
| JP7509768B2 JP7509768B2 (ja) | 2024-07-02 |
Family
ID=64453279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523599A Active JP7509768B2 (ja) | 2018-11-05 | 2019-10-30 | インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20210386864A1 (enExample) |
| EP (1) | EP3876993A1 (enExample) |
| JP (1) | JP7509768B2 (enExample) |
| KR (1) | KR20210100607A (enExample) |
| CN (1) | CN113260382B (enExample) |
| AR (1) | AR116999A1 (enExample) |
| AU (1) | AU2019376293A1 (enExample) |
| BR (1) | BR112021008232A2 (enExample) |
| CA (1) | CA3118041A1 (enExample) |
| CL (1) | CL2021001142A1 (enExample) |
| EA (1) | EA202191244A1 (enExample) |
| IL (1) | IL282748B2 (enExample) |
| MX (1) | MX2021005134A (enExample) |
| SG (1) | SG11202104491SA (enExample) |
| TW (1) | TW202039005A (enExample) |
| WO (1) | WO2020094471A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3313523A2 (en) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of ksp inhibitors |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| CN110312534B (zh) | 2016-12-21 | 2023-04-04 | 拜耳制药股份公司 | 具有酶促可裂解基团的抗体-药物-缀合物(adc) |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| EA202191244A1 (ru) * | 2018-11-05 | 2021-10-11 | Байер Фарма Акциенгезельшафт | Новые цитостатические конъюгаты с лигандами интегрина |
| WO2023057814A1 (en) | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
| WO2023057813A1 (en) | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
| WO2023057812A1 (en) | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder |
| JP2025537882A (ja) | 2022-11-17 | 2025-11-20 | ハンス－ゲオルク レルケン | 腫瘍微小環境において切断可能な小分子－薬物コンジュゲート |
| WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
| US20240376212A1 (en) * | 2023-04-25 | 2024-11-14 | Targetthera Llc | Alpha v-integrin targeted small molecule drug conjugates |
| CN119143798B (zh) * | 2024-08-01 | 2025-09-30 | 河北医科大学 | 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4943579A (en) | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
| DE4229903A1 (de) | 1992-09-08 | 1994-03-10 | Bayer Ag | Neue Acetale von Ketophosphamid und Alkylglycosiden |
| DE4236237A1 (de) | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
| US5646159A (en) | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
| CA2265484C (en) | 1996-09-10 | 2008-12-02 | The Burnham Institute | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| EP1238678A1 (en) * | 2001-03-08 | 2002-09-11 | Bayer Aktiengesellschaft | Enzyme-activated cytostatic conjugates with integrin ligands |
| TW201004647A (en) * | 2008-05-20 | 2010-02-01 | Sigma Tau Ind Farmaceuti | Novel dual targeting antitumoural conjugates |
| EA202191244A1 (ru) * | 2018-11-05 | 2021-10-11 | Байер Фарма Акциенгезельшафт | Новые цитостатические конъюгаты с лигандами интегрина |
-
2019
- 2019-10-30 EA EA202191244A patent/EA202191244A1/ru unknown
- 2019-10-30 SG SG11202104491SA patent/SG11202104491SA/en unknown
- 2019-10-30 MX MX2021005134A patent/MX2021005134A/es unknown
- 2019-10-30 US US17/290,911 patent/US20210386864A1/en not_active Abandoned
- 2019-10-30 JP JP2021523599A patent/JP7509768B2/ja active Active
- 2019-10-30 EP EP19791285.0A patent/EP3876993A1/en active Pending
- 2019-10-30 CN CN201980087910.9A patent/CN113260382B/zh active Active
- 2019-10-30 KR KR1020217015569A patent/KR20210100607A/ko not_active Ceased
- 2019-10-30 BR BR112021008232-8A patent/BR112021008232A2/pt not_active Application Discontinuation
- 2019-10-30 CA CA3118041A patent/CA3118041A1/en active Pending
- 2019-10-30 AU AU2019376293A patent/AU2019376293A1/en not_active Abandoned
- 2019-10-30 WO PCT/EP2019/079601 patent/WO2020094471A1/en not_active Ceased
- 2019-10-30 IL IL282748A patent/IL282748B2/en unknown
- 2019-11-01 TW TW108139645A patent/TW202039005A/zh unknown
- 2019-11-06 AR ARP190103243A patent/AR116999A1/es not_active Application Discontinuation
-
2021
- 2021-04-30 CL CL2021001142A patent/CL2021001142A1/es unknown
-
2024
- 2024-06-14 US US18/744,084 patent/US20240325553A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7509768B2 (ja) | インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート | |
| JP2022506299A5 (enExample) | ||
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| TW201740979A (zh) | 熱休克蛋白（ｈｓｐ）９０抑制劑藥物共軛物 | |
| CN113474014A (zh) | 放射性免疫缀合物与dna损伤和修复抑制剂组合疗法 | |
| US20230302144A1 (en) | Porphyrin Compounds and Compositions Useful for Treating Cancer | |
| US20250032477A1 (en) | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders | |
| JP2023545871A (ja) | 反応性共役体 | |
| US20240423973A1 (en) | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders | |
| HK40049734B (zh) | 含整合素配体的细胞抑制性缀合物 | |
| HK40049734A (en) | Cytostatic conjugates with integrin ligands | |
| HK40060346A (en) | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy | |
| HK40008068B (zh) | 用於治疗癌症的卟啉化合物和组合物 | |
| WO2019115609A1 (en) | Saccharide functionalised carbaborane conjugates of human peptide y | |
| HK1241882A1 (en) | Benzyl substituted indazoles as bub1 inhibitors |